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Abstract (word count: 246245) 1 
Background: Asthma and other Th2 inflammatory conditions have been associated with increased 2 
susceptibility to viral infections. The mechanisms by which Th2 cytokines can influence immune 3 
responses to infections are largely unknown. 4 
Methods: We measured the effects of Th2 cytokines (IL-4 and IL-13) on bronchial epithelial cell 5 
innate immune antiviral responses by assessing interferon (IFN-β and IFN-λ1) induction following 6 
rhinovirus (RV)-16 infection. We also investigated the modulatory effects of Th2 cytokines on 7 
signalling pathways involved in the rhinovirus-induced interferon production and inflammatory 8 
cascade including Toll-like receptor (TLR)-3, interferon-responsive factor (IRF)-3, and nuclear 9 
factor (NF)-kB., i.e. key molecules and transcription factors involved in the rhinovirus-induced 10 
interferon production and inflammatory cascade. Pharmacological and redox modulation by the 11 
reducing agent N-acetylcysteine onof these pathways was also testedassessed.  12 
Results: Th2 cytokines impaired RV16-induced interferon production, increased rhinovirus 13 
replication and impaired TLR3 expression in bronchial epithelial cells. These results were 14 
replicated in vivo: we found increased IL-4 mRNA levels in nasal epithelial cells from nasal 15 
brushing of atopic rhinitis patients and a parallel reduction of TLR3 expression and increased RV16 16 
replication compared to non-atopic subjects. Mechanistically, Th2 cytokines impaired RV-16 17 
induced activation of IRF3, but had no effects on RV16-induced NF-kB activation in bronchial 18 
epithelial cell cultures. N-acetylcysteine and phosphoinositide 3-kinase (PI3k) inhibitor restored the 19 
inhibitory effects of Th2 cytokines over RV-16 induced activation of IRF3 and production of IFNs.  20 
Conclusions: IL-4 and IL-13, through inhibition of TLR3 expression and oxidant-mediated 21 
inhibition of signalling (IRF-3,), impair immune response to RV-16 infection. These data suggest 22 
that Th2 conditions increase susceptibility to infections and identify a pharmacological 23 
approachapproaches with potential to restore impaired immune response in these conditions. 24 
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  1 
Introduction 2 
Asthma is a chronic disorder of the airways that is typically inflammatory in nature and 3 
affects millions of children and adults (1).(1).  4 
Viral infections of the respiratory tract early in life are associated with an increased risk of 5 
developing asthma later in life and are also the most frequent causes of asthma exacerbations in 6 
both children and adults (2). Rhinoviruses are the respiratory virus type that is most frequently 7 
detected during asthma exacerbations (3). The innate immune response is at the forefront of the 8 
defence against respiratory infections. Impaired innate immune responses have been reported to be 9 
a possible mechanism of increased susceptibility to infections among asthmatic patients (2,4,5).(2). 10 
Rhinoviruses are the respiratory virus type that is most frequently detected during asthma 11 
exacerbations (3). The innate immune response is at the forefront of the defence against respiratory 12 
infections.  13 
Impaired innate immune responses have been reported to be a possible mechanism of 14 
increased susceptibility to infections among asthmatic patients (2,4,5). The molecular mechanisms 15 
underlying such a deficiency are still largely unknown.  16 
The cytokines produced by the Th2 subset of lymphocytes, such as IL-4 and IL-13, have 17 
been proven to be important drivers of allergic airway inflammation in asthma, although a) the 18 
mechanisms underlying their roles in the complex pathogenesis are still widely debated andb) not 19 
all asthmatic patients have higha preponderant Th2 oriented inflammatory profile in the airways (6). 20 
We recently documented that in vivo Th2 inflammation is associated with impaired ex vivo 21 
immune responses to rhinovirus infection in bronchial epithelial cells from asthmatic children and 22 
also in cells from atopic children without any established clinical manifestations of asthma (7). 23 
These data accord with previous in vitro (8-10) and in vivo data (11) and suggest that the Th2 24 
inflammation influences the integrity of the innate immune responses and the outcomes of 25 
infections.  26 
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 5 
Oxidative stress has previously been found to influence the molecular pathways that are 1 
commonly involved in rhinovirus-induced intracellular signalling and proinflammatory activities 2 
(12,13). Furthermore, it has been shown that oxidative stress can impair innate immune responses 3 
by interfering with the intracellular interferon signalling (14,15). Thus, modulation of the 4 
intracellular redox state represents a potential pharmacological target for interfering with the 5 
intimate mechanisms that are related to viral infection and the immunological and inflammatory 6 
substrates and consequences of such infections. 7 
(6) nor allergen driven clinical manifestations. We recently documented that in vivo Th2 8 
inflammation is associated with impaired ex vivo immune responses to rhinovirus infection in 9 
bronchial epithelial cells from asthmatic children and also in cells from atopic children without any 10 
established clinical manifestations of asthma (7). These data accord with previous in vitro (8-10) 11 
and in vivo data (11) suggest that the Th2 inflammation influences the integrity of the innate 12 
immune responses and the outcomes of infections. Thus, intercepting the mechanisms of Th2 13 
interference upon innate immune response may improve the ability of counteract the susceptibility 14 
to infections in these clinical conditions.  15 
Oxidative stress has previously been found to influence the molecular pathways that are 16 
commonly involved in rhinovirus-induced intracellular signalling and proinflammatory activities 17 
(12,13). Furthermore, it has been shown that oxidative stress can impair innate immune responses 18 
by interfering with the intracellular interferon signalling (14,15). In addition, phosphoinositide 3-19 
kinases (PI3K) is a large family of intracellular signalling kinases involved in the both innate 20 
immune response to infections and Th2 inflammation (16-20). Thus, modulation of the intracellular 21 
redox state and of PI3k immunoregulatory activities represent potential pharmacological targets of 22 
interference with the substrates of immunological and inflammatory responses to viral infections.  23 
Here, we evaluated the effects of Th2 cytokines (IL-4 and IL-13) on innate immune 24 
responses as assessed by type I (IFN-β) and type III (IFN-λ1) interferon production against 25 
rhinovirus infection in bronchial epithelial cells. We also identifiedevaluated the signalling 26 
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 6 
pathways involved in the inhibitory effects of Th2 cytokines over key molecules (TLR-3) and 1 
transcription factors (IRF3 and NF-kB) involved in the innate immune responses to viral 2 
infectionsrhinovirus and tested potential methods of pharmacological modulation.  3 
 4 
5 
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 7 
Methods 1 
Cell cultures and in vitro rhinovirus infections 2 
The immortalized human bronchial epithelial cell line BEAS-2B was obtained from the 3 
American Type Culture Collection (Rockville, Md, USA) and cultured as previously described (16). 4 
Primary human bronchial epithelial cells (HBECs) were obtained from bronchial brushings of non-5 
atopic, non-asthmatic and non-smoking subjects (who underwent bronchoscopy for clinical reasons 6 
– Supplementary Table 1) and cultured as previously described (7,16,17).  7 
Primary epithelial cells of the nasal mucosae of five atopic rhinitis and six non-atopic 8 
healthy non-smoker volunteers were harvested by nasal scraping and freshly cultured in BEG 9 
medium.The immortalized human bronchial epithelial cell line BEAS-2B was obtained from the 10 
American Type Culture Collection (Rockville, Md, USA) and cultured as previously described (21). 11 
Primary human bronchial epithelial cells (HBECs) were obtained from bronchial brushings of non-12 
atopic, non-asthmatic and non-smoking subjects (who underwent bronchoscopy for clinical reasons 13 
– Supplementary Table 1) and cultured as previously described (7,21,22).  14 
Primary epithelial cells of the nasal mucosae of five atopic rhinitis and six non-atopic 15 
healthy non-smoker volunteers were harvested by nasal scraping and freshly cultured in BEG 16 
medium (Supplementary Table 2). When confluent, total RNA was extract according to 17 
manufacturer’s instructions (Qiagen). Atopic status was defined as the presence of at least one 18 
positive response to skin pricks tests for common local aeroallergens (the 19 
The demographic characteristics are reportedof the patients enrolled in the online supporting 20 
information).  21 
Thestudy and the experimental conditions of the cell cultures and stimulationstimulations 22 
are detailed in the online supporting information and in Supplementary Table 1 and 2.  23 
The study was approved by the local ethics committee of the University Hospital of Ferrara, 24 
and informed consent was obtained from each participant in accordance with the principles outlined 25 
in the Declaration of Helsinki. 26 
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 8 
 1 
Viral stocks 2 
Rhinovirus type 16 (RV16) was obtained from the Health Protection Agency Culture 3 
Collections, Salisbury, United Kingdom and used for all of the experimental conditions described. 4 
The virus was used at a multiplicity of infection (MOI) of 5 in all experiments (1823). 5 
 6 
Quantitative TaqMan real-time RT-PCR 7 
Quantitative real-time PCR was performed with specific primers and probes for rhinovirus, 8 
IFN-β, IFN-λ (specific for IFN-λ1), CXCL8 (Qiagen), TLR3 (Qiagen), and IL-4 (Qiagen) as 9 
detailed elsewhere (7,16,17). Quantitative real-time PCR results were normalized to 18S rRNA or 10 
GAPDH expression (housekeeping genes). Interferon mRNA, CXCL8 mRNA, and viral RNA 11 
(vRNA) expression were normalized to 18S rRNA levels, compared with standard curves, and 12 
expressed as copy numbers per microgram of RNA. 13 
Quantitative real-time PCR was performed with specific primers and probes for rhinovirus, 14 
IFN-β, IFN-λ (specific for IFN-λ1), CXCL8 (Qiagen), TLR3 (Qiagen), and IL-4 (Qiagen) as 15 
detailed elsewhere (7,21,22). Quantitative real-time PCR results were normalized to 18S rRNA or 16 
GAPDH expression (housekeeping genes). Interferon mRNA, CXCL8 mRNA, and viral RNA 17 
(vRNA) expression were normalized to 18S rRNA levels, compared with standard curves, and 18 
expressed as log10 copy numbers per microgram of RNA. An arbitrary level equal to 1 copy of IFN-19 
beta, -lambda mRNA or vRNA was assigned if undetectable.  20 
 21 
Interferon and CXCL8 protein assays 22 
The enzyme-linked immunosorbent assays (ELISA) used for the detections of IFN-β, IFN-λ, 23 
and CXCL8 levels in cell-culture supernatants were performed according to the manufacturers’ 24 
instructions. The sensitivities, specificities, and sources for the individual ELISAs have been 25 
previously detailed (7)(7). 26 
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 1 
Measurement of transcription factor activation  2 
Nuclear extracts were prepared from the BEAS2B cells using a nuclear protein extraction kit 3 
(Active Motif, Rixensart, Belgium). Activated NFkB, IRF3 and STAT1 in 10-µg nuclear extracts 4 
were detected by evaluating their bindings to oligonucleotides targeting each binding site using 5 
ELISA-based assays (TransAM Transcription
 
Factor Assay kits for NFkB, IRF3 and the STAT 6 
family; Active Motif, La Hulpe, Belgium) following the manufacturer’s recommendations. 7 
 8 
Statistical analyses 9 
The data are expressed as the means and the standard errors of the means of at least 4 10 
experiments. Differences between the conditions at each time point were calculated with unpaired t 11 
tests. Multiple comparisons were first analysed with ANOVAs. When significant (p< 0.05) 12 
differences between groups/conditions were found, post hoc analyses were performed with paired 13 
or unpaired t-tests as appropriate. Values below .05 were considered significant. In cases of 14 
multiple comparisons, the reported p values refer to analyses that were adjusted with the Bonferroni 15 
correction.Comparisons between conditions were performed by means of paired or unpaired non 16 
parametric tests (Wilcoxon test or Mann-Whitney test respectively). After the evaluation of the 17 
effects of rhinovirus infection (e.g. on interferon induction and/or transcription factors activation), 18 
in case of multiple tests, paired comparisons were performed using a Hierarchical method to control 19 
for multiplicity based on concentration, timing or modulatory intervention. A P-value of <0·05 was 20 
considered significant. All analyses were performed with GraphPad Prism 5.0 for Windows 21 
(GraphPad Software, Inc., La Jolla, California). 22 
23 
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 10
Results 1 
Effects of Th2 cytokines on rhinovirus-induced interferon production and rhinovirus 2 
replication 3 
To evaluate the effects of the Th2 status of the environment on rhinovirus-induced interferon 4 
(IFN) production, human bronchial epithelial cells (HBECs) and BEAS-2B cells were pre-treated 5 
with IL-4 and IL-13 prior to infection. Twenty-four-hour pre-treatment with IL-4 and IL-13 6 
produced significant dose-dependent inhibition of rhinovirus-induced IFN-β mRNA expression and 7 
IFN-β protein release at 8 hrs after infection in both the BEAS-2B cell line (Supplementary Figure 8 
1) and in HBECs (Figure 1A, 1C and 1E). Rhinovirus mediated induction of IFN-λ mRNA 9 
expression was also diminished 8 hrs after infection in both the BEAS-2B (Supplementary Figure 10 
1) and HBECs (Figure 1B and 1D). IFN-λ protein was undetectable in the cell culture supernatants 11 
of any of the experimental conditions assessed here. Neither IL-4 nor IL-13 had any modulatory 12 
effects on the rhinovirus-induced pro-inflammatory cytokine production, such as CXCL8 (Figure 13 
1F). IL-2 (used as control; Figure 1G and 1H) had no effect on rhinovirus-induced IFN induction. 14 
The inhibitory effect of Th2 cytokine pre-treatment on IFN production was observed at 8 but not 24 15 
hrs after the infection (Figure 2A-D). 16 
The impaired IFN expression following rhinovirus infection in the cell cultures that were 17 
pre-treated with Th2 cytokines was paralleled by increased rhinovirus replication in both the BEAS-18 
2B (data not shown) and HBECs (Figure 2E, 2F). Levels of IFN-β and IFN-λ mRNA and of 19 
rhinovirus vRNA were virtually undetectable (close to the lowest limit of detection) in uninfected 20 
cells and in cells stimulated only with Th2 cytokines (Figure 1 and 2).  21 
 22 
Effects of Th2 cytokines on rhinovirus-induced activation of transcription factors involved in 23 
interferon production and signalling. 24 
To investigate the mechanisms involved in the inhibitory effects of the Th2 cytokines on 25 
rhinovirus-induced IFN production, we evaluated the effects of IL-4 and IL-13 on rhinovirus-26 
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 11
induced activation of the transcription factors involved in interferon production, such as nuclear 1 
factor-kB (NF-kB) and IFN regulatory factor (IRF)-3 (19)(24), and STAT1, which is a transcription 2 
factor that is activated by interferon-receptor engagement, and this activation leads to the 3 
transcription of IFN-stimulated genes (20).(25). NF-kB, IRF-3 and STAT1 were activated 2 hrs 4 
after rhinovirus infection (Figure 3A-C). In the BEAS-2B epithelial cells, 12-hrs pre-treatment with 5 
IL-4 (50 ng/ml) and IL-13 (25 ng/ml) significantly inhibited rhinovirus-induced IRF3 activation and 6 
subsequent STAT1 activation (Figure 3B and 3C) but also resulted in a slight increase of NF-kB 7 
activation that was not statistically significant (Figure 3A).  8 
 9 
Effects of antioxidants on Th2 cytokine-induced impairment of the innate immune response to 10 
rhinovirus. 11 
Pre-treatment with exogenous NAC (10 mM) 30 min before rhinovirus infection abolished 12 
the inhibitory effect of the 24-hr pre-treatment with Th2 cytokines on rhinovirus-induced IRF-3 13 
(Figure 4A) and STAT1 activations (Figure 4B) and restored the rhinovirus-induced expressions of 14 
IFN-λ (Figure 4C) and IFN-β mRNA (Figure 4D).  15 
 16 
Effects of Phosphoinositide 3-kinases (PI3K) on Th2 cytokine-induced impairment of the 17 
innate immune response to rhinovirus. 18 
 We found that pre-treatment with the phosphoinositide 3-kinases (PI3k) inhibitor LY294002 19 
(3.3 uM) before rhinovirus infection restored the inhibitory effect of Th-2 cytokines on rhinovirus 20 
induced IRF-3 activation, suggesting that the inhibition of phosphoinositide 3-kinases counteract 21 
the Th-2 induced impairment of the innate immune response to rhinovirus (Figure 4E). 22 
 23 
Effects of Th2 cytokines and oxidants on TLR3 expression.  24 
TLR-3 it is one of the key molecule activated by double stranded RNA produced during 25 
rhinovirus infection which in turn activates transcription factors such as nuclear factor (NF)-kB and 26 
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 12
IFN regulatory factor (IRF)-3/7 leading to the production of proinflammatory cytokines, 1 
chemokines and antiviral molecules including interferons (26-30). Twenty-four-hour IL-4 pre-2 
treatment significantly inhibited the baseline expression of TLR3 in the respiratory epithelial cells 3 
(Figure 5A). This inhibition was not affected by concomitant cell exposure to the antioxidant N-4 
acetyl cysteine (NAC, 10 mM; figure 5A).  5 
The expression of TLR3 mRNA was evaluated in the nasal epithelial cells from atopic 6 
rhinitis patients. Compared to the non-atopic healthy subjects, the expression of IL-4 mRNA was 7 
significantly higher in the primary nasal cells obtained from patients with atopic rhinitis, which 8 
confirms the Th2-related nature of the inflammatory process present in the upper airways of these 9 
subjects (Figure 5B). Conversely, TLR3 mRNA expression was significantly lower in the primary 10 
nasal cells obtained from patients with atopic rhinitis compared to those of healthy subjects (Figure 11 
5C).  Consistent with the latter finding, increased viral replication was observed in the primary 12 
cultures of the nasal epithelial cells from the atopic subjects compared to those of the controls 13 
(Figure 5D). 14 
 15 
16 
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Discussion 1 
Asthma is a chronic inflammatory disorder of the airways that is typically, butalthough not 2 
always, characterized by enhanced Th2-type inflammation (21).(31). In this study, we documented 3 
that Th2 cytokines (IL-4 and IL-13) impaired components of innate immunity, such as the 4 
production of types I (IFN- β) and III IFN (IFN- λ), in response to rhinovirus infection. The 5 
inhibitory effects of Th2 inflammation on interferon production can favour increased susceptibility 6 
to infections in asthmatic patients. 7 
The airway epithelial layer is the natural site at which respiratory viral infections occur. 8 
Recent investigations have evaluated the crosstalk between Th2 inflammation and antiviral 9 
interferon production at the bronchial epithelial level. Moriwaki and colleagues found that Th2 (IL-10 
13)-deficient mice exhibit greater enhancements of IFN-λ expression following intratracheal 11 
instillation of poly-IC (which mimicked viral infection) than wild-type mice, whereas IFN-λ 12 
expression following poly-IC is absent in the lungs of mice with allergen-induced asthma in which 13 
Th2 cytokines plays a central pathogenic role (8). Eosinophils are the effector cells of the Th2 14 
inflammatory cascade. It has recently been shown that rhinovirus infection of bronchial epithelial 15 
cells cocultured with eosinophils results in the impairment of interferon-β and λ production and 16 
increases rhinovirus replication (9). On the other side, previous studies have reported that 17 
interferon-λ down-regulates the Th2 inflammatory response (22-25). Taken together, these data 18 
support the existence of a counter-regulatory relationship between Th2 inflammation and the innate 19 
immune response.  20 
The mechanisms by which Th2 inhibits virus-induced interferon production at the airway 21 
epithelial level remain largely unexplored. Double-stranded RNA (dsRNA) produced during viral 22 
infection and replication is an important stimulus of the host innate immune response. This dsRNA 23 
is recognized and engaged by TLR3, which in turn activates transcription factors, such as nuclear 24 
factor (NF)-kB and IFN regulatory factor (IRF)-3/7, which lead to the production of 25 
proinflammatory cytokines, chemokines and antiviral molecules including interferons (26-28). 26 
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 14
Previous studies have shown that oxidative stress negatively interferes with intracellular interferon 1 
signalling, including IRF3 activation (14,15), but can amplify the activation of the transcription 2 
factors involved in virus-induced interferon production and/or inflammation, such as NF-kB (29). It 3 
has also been reported that the exposure of epithelial cells to IL-4 and IL-13 cytokines leads to 4 
increased intracellular oxidative burst (30-32). In this study, we found that the stimulation of the 5 
bronchial epithelial cell line BEAS-2B with Th2 inflammatory cytokines (IL-4 and IL-13) led to 6 
reduced baseline expression of TLR3 via a mechanism that was not mediated by oxidants. Similar 7 
results have previously been shown in human intestinal epithelial cells (33). In accordance with 8 
previous observations (14), we also found that Th2 cytokines inhibited rhinovirus-induced IRF3 9 
activation via a mechanism that can be modulated by antioxidants. Thus, the impaired IRF3 10 
activation documented here might be the consequence of the Th2 mediated impairment of TLR3 11 
expression (which leads to impaired IRF3 activation) and also the consequence of a direct Th2-12 
induced oxidant-mediated effect. Interestingly, we showed for the first time in the present study 13 
reduced in vivo levels of TLR3 associated with enhanced Th2 inflammation in the nasal epithelial 14 
cells of atopic rhinitis patients compared to normal controls. Interestingly, recent in vivo 15 
observations suggest that the expression (34) and activity (35) of TLR3 are not impaired in the 16 
bronchial epithelial cells of mild asthmatic subjects compared to healthy subjects. These data might 17 
suggest that mechanisms other than those associated with the TLR pathways are involved in the 18 
impairment of interferon production in the bronchial epithelial cells of asthmatic subjects. It is 19 
possible than such impairments develop only in specific subgroups of patients, e.g., those with more 20 
severe asthma and those more prone to infections, in which Th2 inflammation is pronounced. It is 21 
also conceivable that impaired TLR3 expression in the upper respiratory tract i.e nasal mucosa 22 
could be a mechanism that is responsible for increased susceptibility that is primarily 23 
compartmentalized to upper respiratory infections in Th2-oriented diseases such as atopic rhinitis.  24 
The outcome of the interferon-activated Janus kinase (JAK) signal transducer and activator 25 
of transcription (STAT) signalling pathway is the transcriptional induction of the expressions of 26 
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genes with antiviral properties. Specifically, STAT1 activation is a common mechanism of the 1 
antiviral actions of Type I (IFN-α and -β), Type II (IFN-γ) and Type III (IFN-λ) interferons (20). 2 
JAK-STAT signalling is activated following interferon-receptor engagement. It has also been 3 
previously shown that oxidative stress directly inhibits interferon-induced JAK-STAT activation 4 
and signalling (15). Therefore, the impairment of STAT1 that we documented in the presence of a 5 
Th2 inflammatory environment can be the result of impaired interferon release and consequent 6 
reduction in IFN-receptor stimulation but also of Th2 mediated oxidative stress being reversed by 7 
antioxidant (N-acetylcysteine) treatment.  8 
NF-kB is a key element in the rhinovirus-induced inflammatory response and might also be 9 
involved in virus-induced interferon production. A recent study showed that rhinovirus-infected 10 
NF-kB p65-deficient mice exhibited reduced neutrophilic inflammation; however, interferon 11 
induction, antiviral responses and viral loads are unaffected (36). In our study, we found that IL-4 12 
stimulation did not impair rhinovirus-induced NF-kB activation. Taken together, these experimental 13 
data confirm that NF-kB is required for pro-inflammatory responses, but its role in interferon 14 
induction by rhinoviruses is redundant, and the data also show that Th2 cytokines do not impair NF-15 
kB activation potentially explaining why IL-4 and IL-13 had no effect on CXCL-8 in our model 16 
system. 17 
The mechanisms by which a Th2 immunologic pattern inhibits virus-induced interferon 18 
production at the airway epithelial level, i.e. at the primary site of respiratory viral infections, 19 
remain largely unexplored. Here we evaluated the effects of Th2 cytokines over TLR-3 molecule 20 
and STAT1, IRF3 and NF-kB transcription factors, i.e. some of the key steps involved in rhinovirus 21 
induced interferon production (26-30). 22 
In line with previous observations (14), we found that Th2 cytokines inhibited rhinovirus-23 
induced IRF3 activation. We also found impaired activation of STAT1 following rhinovirus 24 
infection in the presence of Th2 cytokines. It has been previously reported that a) the exposure of 25 
epithelial cells to IL-4 and IL-13 cytokines leads to increased intracellular oxidative burst (32-34) 26 
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and b) oxidative stress negatively interferes with intracellular interferon signalling, including IRF3 1 
activation (14,15) and interferon-induced JAK-STAT activation and signalling (15). Interestingly, 2 
here we show that the antioxidant NAC restores rhinovirus-mediated activation of IRF3 and STAT1 3 
and the downstream IFN-β and IFN-λ mRNA induction. These data suggest that the inhibition of 4 
oxidative stress represents a possible pharmacological approach to potentiate the innate immune 5 
responses to rhinovirus in a Th2 inflammatory milieu.  6 
Oxidative stress can also amplify the activation of the NF-kB transcription factors involved 7 
in virus-induced interferon production and/or inflammation (35). A recent study showed that 8 
rhinovirus-infected NF-kB p65-deficient mice exhibited reduced neutrophilic inflammation, while 9 
interferon induction, antiviral responses and viral loads were unaffected (29). In our study we found 10 
that IL-4 stimulation did not impair rhinovirus-induced NF-kB activation, while it affected 11 
rhinovirus induced interferon induction. Taken together, these experimental data confirm that NF-12 
kB is required for pro-inflammatory responses, but its role in interferon induction by rhinoviruses is 13 
not essential an may be redundant.  The fact that Th2 cytokines do not impair NF-kB activation is 14 
consistent with IL-4 and IL-13 having no effect on CXCL-8 induction in our model.  15 
The stimulation of the bronchial epithelial cell line BEAS-2B with Th2 inflammatory 16 
cytokines (IL-4 and IL-13) led to reduced baseline expression of TLR3 via a mechanism that was 17 
not mediated by oxidants. Similar results have previously been shown in human intestinal epithelial 18 
cells (36). Thus, the impaired IRF3 activation documented here might be the consequence of the 19 
Th2 mediated impairment of TLR3 expression (which leads to impaired IRF3 activation) and also 20 
the consequence of a direct Th2-induced oxidant-mediated effect. Interestingly, we showed for the 21 
first time in the present study reduced in vivo levels of TLR3 associated with enhanced Th2 22 
inflammation in the nasal epithelial cells of atopic rhinitis patients compared to normal controls. In 23 
line with these concepts, it has been recently shown that house dust mite (HDM)-sensitised mice 24 
have impaired rhinovirus-induced interferon production that is paralleled by a strong Th2-skewed 25 
inflammatory airway response (37). In addition, the pre-exposure of airway epithelial cells to HDM 26 
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before rhinovirus infection deregulates TLR3-mediated production of cytokines and inflammatory 1 
mediators (38). Therefore HDM could suppress the IFN system either directly or via a Th-2 2 
mediated pathway, the latter requiring further investigation given that IL-4/IL-13 signalling is quite 3 
distinct from HDM signalling. Interestingly, recent in vivo observations suggest that the expression 4 
(39) and activity (40) of TLR3 are not impaired in the bronchial epithelial cells of mild asthmatic 5 
subjects compared to healthy subjects. These data might suggest that mechanisms other than those 6 
associated with the TLR pathways are involved in the impairment of interferon production in the 7 
bronchial epithelial cells of asthmatic subjects. It is possible that such impairments favour increased 8 
susceptibility to infections in specific subgroups of patients, e.g., those with more severe asthma 9 
and/or those patients with a predominant Th2 airway inflammation where such impairment is 10 
expected to be more pronounced-. It is also conceivable that impaired TLR3 expression in the upper 11 
respiratory tract i.e nasal mucosa could be a mechanism that is responsible for increased 12 
susceptibility that is primarily compartmentalized to upper respiratory infections in Th2-oriented 13 
diseases such as atopic rhinitis.  14 
 Finally, we recently found that asthmatic children, irrespective of atopic status, and atopic 15 
children, irrespective of the presence of asthma, exhibit impaired immune responses at the bronchial 16 
epithelial level in terms of type I (IFN-β) and type III (IFN-λ) production after rhinovirus infection. 17 
Enhanced Th2-mediated airway inflammation is the common biological substrate between these 18 
children (7)(7). In this study, we documented that the development of a Th2 environment negatively 19 
affects the molecular mechanisms that govern the innate immune responses to viral infections. 20 
Indeed, TLR3 expression was found to be impaired in the epithelial cells of the nasal mucosa of 21 
atopic patients. In accordance with this concept, we observed increased viral replication associated 22 
with increased IL-4 expression in the nasal mucosa of atopic rhinitis patients compared to normal 23 
subjects. These data confirmsupport the concept that impaired immune responses to viral infection 24 
are not exclusive tothe Th2 inflammation can dampen the anti-viral response and make the Th2 25 
environment even without asthma but are shared with other Th2 -driven diseases (e.g. allergic 26 
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rhinitis).) a more susceptible condition to viral infections. This concept is consistent with recent 1 
observations that subjects with atopic diseases (including asthma, rhinitis and dermatitis) 2 
experience more frequent upper and lower respiratory tract infections than do non-atopic controls 3 
(37). The inhibition of oxidative stress represents a possible pharmacological approach to potentiate 4 
the innate immune responses of these patients and to reduce their susceptibility to infections.(41). In 5 
this scenario any pharmacological approach able to down-regulate Th2 inflammation has the 6 
potential to recover a defective innate immune responses.  Previous studies showed that: a) IL-4 7 
intracellular signalling leads to the activation of PI3k (20) and b) inhibition of PI3k resulted in 8 
attenuated Th2 inflammatory response in a mouse model of allergic asthma (17) and enhanced TLR 9 
signalling (19,42). Interestingly, in our study we found that the inhibition of PI3k restored the 10 
inhibitory effect of 24 hr pre-treatment with Th-2 cytokines on rhinovirus induced IRF-3 activation, 11 
suggesting that the inhibition of phosphoinositide 3-kinases counteract the Th-2 induced 12 
impairment of the innate immune response to rhinovirus.  13 
In conclusion we showed that Th2 inflammation can dampen the anti-viral response and 14 
increase susceptibility viral infections of Th2 driven immunological conditions. In our experimental 15 
setting, pre-treatment with either antioxidants or inhibitors of PI3ks prevented the Th2-induced 16 
impairment of innate immune response to rhinovirus infection. Further studies are needed to 17 
elucidate more extensively at system biology level the complex interactions in the signalling 18 
pathways that links Th2 inflammation to impaired immune response to infections.  19 
20 
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Figure legends 1 
Figure 1. Dose-response effects of 24-hr pre-treatment with Th2 cytokines (IL-4: panel A and B – 2 
IL-13: panel C and D) on rhinovirus-induced interferon mRNA induction (IFN-β: panel A and C 3 
and IFN-λ: panel B and D) in human bronchial epithelial cells (HBEC) of non-atopic, non-4 
asthmatic subjects. Panel E: Effects of 24-hr pre-treatment with Th2 cytokines (IL-4 and IL-13) on 5 
rhinovirus (RV) 16-induced IFN-β production in HBECs (*p<0.01 vs. untreated and uninfected 6 
cells and IL-4- or IL-13-treated cells; ^p<0.05 vs. RV16 infected cells). Panel F: Effects of Th2 7 
cytokines (IL-4: 50 ng/ml and IL-13: 25 ng/ml) on rhinovirus-induced CXCL-8 production in 8 
HBECs (*p<0.01 vs. untreated and uninfected cells and IL-4- or IL-13-treated cells). Effects of IL-2 9 
on rhinovirus-induced IFN-β mRNA (Panel G) and IFN-λ mRNA (Panel H) in HBECs 10 
(***p<0.001; **p<0.01; *p<0.05; RV16: rhinovirus 16; f-RV16: cells inoculated with virus stock 11 
from which the virus had been removed by molecular weight filtration) (all panels n=6). 12 
 13 
Figure 2. Time course of the effects of 24-hr pre-treatment with Th2 cytokines (IL-4 and IL-13) on 14 
rhinovirus-induced IFN-β and IFN-λ mRNA induction and rhinovirus replication in human 15 
bronchial epithelial cells (HBECs). (**p<0.01; *p<0.05) (all panels n=6). 16 
 17 
Figure 3. Effects of 24-hr pre-treatment with Th2 cytokines (IL-4: 50 ng/ml and IL-13: 25 ng/ml) 18 
on rhinovirus-induced nuclear factor (NF)-kB (Panel A), interferon responsive factor 3 (IRF3; Panel 19 
B) and STAT1 (Panel C) activation in BEAS-2b cell (**p<0.01 and *p<0.05 vs. untreated and 20 
uninfected cells and IL-4- or IL-13-treated cells; ^p<0.05 vs. rhinovirus (RV) 16-infected cells) (all 21 
panels n=4). 22 
 23 
Figure 4. Effects of 24-hr pre-treatment with IL-4 (50 ng/ml) on rhinovirus (RV) 16-induced 24 
interferon responsive factor 3 (IRF3; Panel A) and STAT1 (Panel B) activation in the presence or 25 
absence of cell exposure to N-acetylcysteine (NAC, 10 mM) 30 minutes prior to infection 26 
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(**p<0.01; p<0.05). Effects of N-acetylcysteine (NAC, 10 mM) 30 minutes prior to infection on the 1 
inhibitory effects of 24-hr pre-treatment with IL-4 (50 ng/ml) on rhinovirus (RV) 16-induced IFN-λ 2 
mRNA in BEAS-2B cells (Panel C) and IFN-β mRNA (Panel D) (ns: not significant; *p<0.05). 3 
(Panel E) Effects of phosphoinositide 3-kinases (PI3k) inhibitor LY294002 (3.3 uM) before 4 
rhinovirus infection on the inhibitory effect of 24-hr pre-treatment with IL-4 (50 ng/ml) on 5 
rhinovirus (RV) 16-induced IRF-3 activation (*p<0.05 vs. untreated and uninfected cells; ^p<0.05 6 
vs. rhinovirus (RV) 16-infected cells and vs cells infected with RV16 and exposed to LY294002) 7 
(all panels n=5). 8 
 9 
Figure 5. Panel A) Effects of 24-hr pre-treatment with Th2 cytokines on TLR3 mRNA expression 10 
in BEAS-2B cells in the presence or absence of cell exposure to N-acetylcysteine. (n=5). The 11 
expression of TLR3 was evaluated by real-time RT-PCR, the results were normalized to GAPDH, 12 
and the expression levels are represented as the fold-changes in expression vs. medium-treated cells 13 
(*p<0.05 vs. medium-treated cells). Panel B) Baseline IL-4 mRNA levels in the primary cell 14 
cultures of epithelial cells of the nasal mucosae of non-atopic (n=6) and atopic (n=5) subjects. Panel 15 
C) Baseline TLR3 mRNA levels in the primary cell cultures of epithelial cells of the nasal mucosae 16 
of non-atopic (n=6) and atopic subjects. (n=5). D) Rhinovirus (RV) 16 vRNA levels 8 hr after the 17 
infection of primary nasal mucosa epithelial cells cultures of non-atopic (n=6) and atopic (n=5) 18 
subjects.   19 
 20 
 21 
22 
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Abstract (word count: 245) 1 
Background: Asthma and other Th2 inflammatory conditions have been associated with increased 2 
susceptibility to viral infections. The mechanisms by which Th2 cytokines can influence immune 3 
responses to infections are largely unknown. 4 
Methods: We measured the effects of Th2 cytokines (IL-4 and IL-13) on bronchial epithelial cell 5 
innate immune antiviral responses by assessing interferon (IFN-β and IFN-λ1) induction following 6 
rhinovirus (RV)-16 infection. We also investigated the modulatory effects of Th2 cytokines on 7 
Toll-like receptor (TLR)-3, interferon-responsive factor (IRF)-3, and nuclear factor (NF)-kB, i.e. 8 
key molecules and transcription factors involved in the rhinovirus-induced interferon production 9 
and inflammatory cascade. Pharmacological and redox modulation of these pathways was also 10 
assessed.  11 
Results: Th2 cytokines impaired RV16-induced interferon production, increased rhinovirus 12 
replication and impaired TLR3 expression in bronchial epithelial cells. These results were 13 
replicated in vivo: we found increased IL-4 mRNA levels in nasal epithelial cells from nasal 14 
brushing of atopic rhinitis patients and a parallel reduction of TLR3 expression and increased RV16 15 
replication compared to non-atopic subjects. Mechanistically, Th2 cytokines impaired RV-16 16 
induced activation of IRF3, but had no effects on RV16-induced NF-kB activation in bronchial 17 
epithelial cell cultures. N-acetylcysteine and phosphoinositide 3-kinase (PI3k) inhibitor restored the 18 
inhibitory effects of Th2 cytokines over RV-16 induced activation of IRF3.  19 
Conclusions: IL-4 and IL-13, through inhibition of TLR3 expression and signalling (IRF-3), impair 20 
immune response to RV-16 infection. These data suggest that Th2 conditions increase susceptibility 21 
to infections and identify pharmacological approaches with potential to restore impaired immune 22 
response in these conditions. 23 
  24 
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 4 
Introduction 1 
Asthma is a chronic disorder of the airways that is typically inflammatory in nature and 2 
affects millions of children and adults (1).  3 
Viral infections of the respiratory tract early in life are associated with an increased risk of 4 
developing asthma later in life and are also the most frequent causes of asthma exacerbations in 5 
both children and adults (2). Rhinoviruses are the respiratory virus type that is most frequently 6 
detected during asthma exacerbations (3). The innate immune response is at the forefront of the 7 
defence against respiratory infections.  8 
Impaired innate immune responses have been reported to be a possible mechanism of 9 
increased susceptibility to infections among asthmatic patients (2,4,5). The molecular mechanisms 10 
underlying such a deficiency are still largely unknown.  11 
The cytokines produced by the Th2 subset of lymphocytes, such as IL-4 and IL-13, have 12 
been proven to be important drivers of allergic airway inflammation in asthma, although a) the 13 
mechanisms underlying their roles in the complex pathogenesis are still widely debated b) not all 14 
asthmatic patients have a preponderant Th2 oriented inflammatory profile in the airways (6) nor 15 
allergen driven clinical manifestations. We recently documented that in vivo Th2 inflammation is 16 
associated with impaired ex vivo immune responses to rhinovirus infection in bronchial epithelial 17 
cells from asthmatic children and also in cells from atopic children without any established clinical 18 
manifestations of asthma (7). These data accord with previous in vitro (8-10) and in vivo data (11) 19 
suggest that the Th2 inflammation influences the integrity of the innate immune responses and the 20 
outcomes of infections. Thus, intercepting the mechanisms of Th2 interference upon innate immune 21 
response may improve the ability of counteract the susceptibility to infections in these clinical 22 
conditions.  23 
Oxidative stress has previously been found to influence the molecular pathways that are 24 
commonly involved in rhinovirus-induced intracellular signalling and proinflammatory activities 25 
(12,13). Furthermore, it has been shown that oxidative stress can impair innate immune responses 26 
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 5 
by interfering with the intracellular interferon signalling (14,15). In addition, phosphoinositide 3-1 
kinases (PI3K) is a large family of intracellular signalling kinases involved in the both innate 2 
immune response to infections and Th2 inflammation (16-20). Thus, modulation of the intracellular 3 
redox state and of PI3k immunoregulatory activities represent potential pharmacological targets of 4 
interference with the substrates of immunological and inflammatory responses to viral infections.  5 
Here, we evaluated the effects of Th2 cytokines (IL-4 and IL-13) on innate immune 6 
responses as assessed by type I (IFN-β) and type III (IFN-λ1) interferon production against 7 
rhinovirus infection in bronchial epithelial cells. We also evaluated the effects of Th2 cytokines 8 
over key molecules (TLR-3) and transcription factors (IRF3 and NF-kB) involved in the innate 9 
immune responses to rhinovirus and tested potential methods of pharmacological modulation.  10 
 11 
12 
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 6 
Methods 1 
Cell cultures and in vitro rhinovirus infections 2 
The immortalized human bronchial epithelial cell line BEAS-2B was obtained from the 3 
American Type Culture Collection (Rockville, Md, USA) and cultured as previously described (21). 4 
Primary human bronchial epithelial cells (HBECs) were obtained from bronchial brushings of non-5 
atopic, non-asthmatic and non-smoking subjects (who underwent bronchoscopy for clinical reasons 6 
– Supplementary Table 1) and cultured as previously described (7,21,22).  7 
Primary epithelial cells of the nasal mucosae of five atopic rhinitis and six non-atopic 8 
healthy non-smoker volunteers were harvested by nasal scraping and freshly cultured in BEG 9 
medium (Supplementary Table 2). When confluent, total RNA was extract according to 10 
manufacturer’s instructions (Qiagen).  11 
The demographic characteristics of the patients enrolled in the study and the experimental 12 
conditions of the cell cultures and stimulations are detailed in the online supporting information and 13 
in Supplementary Table 1 and 2.  14 
The study was approved by the local ethics committee of the University Hospital of Ferrara, 15 
and informed consent was obtained from each participant in accordance with the principles outlined 16 
in the Declaration of Helsinki. 17 
 18 
Viral stocks 19 
Rhinovirus type 16 (RV16) was obtained from the Health Protection Agency Culture 20 
Collections, Salisbury, United Kingdom and used for all of the experimental conditions described. 21 
The virus was used at a multiplicity of infection (MOI) of 5 in all experiments (23). 22 
 23 
Quantitative TaqMan real-time RT-PCR 24 
Quantitative real-time PCR was performed with specific primers and probes for rhinovirus, 25 
IFN-β, IFN-λ (specific for IFN-λ1), CXCL8 (Qiagen), TLR3 (Qiagen), and IL-4 (Qiagen) as 26 
Page 39 of 63 Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 7 
detailed elsewhere (7,21,22). Quantitative real-time PCR results were normalized to 18S rRNA or 1 
GAPDH expression (housekeeping genes). Interferon mRNA, CXCL8 mRNA, and viral RNA 2 
(vRNA) expression were normalized to 18S rRNA levels, compared with standard curves, and 3 
expressed as log10 copy numbers per microgram of RNA. An arbitrary level equal to 1 copy of IFN-4 
beta, -lambda mRNA or vRNA was assigned if undetectable.  5 
 6 
Interferon and CXCL8 protein assays 7 
The enzyme-linked immunosorbent assays (ELISA) used for the detections of IFN-β, IFN-λ, 8 
and CXCL8 levels in cell-culture supernatants were performed according to the manufacturers’ 9 
instructions. The sensitivities, specificities, and sources for the individual ELISAs have been 10 
previously detailed (7). 11 
 12 
Measurement of transcription factor activation  13 
Nuclear extracts were prepared from the BEAS2B cells using a nuclear protein extraction kit 14 
(Active Motif, Rixensart, Belgium). Activated NFkB, IRF3 and STAT1 in 10-µg nuclear extracts 15 
were detected by evaluating their bindings to oligonucleotides targeting each binding site using 16 
ELISA-based assays (TransAM Transcription
 
Factor Assay kits for NFkB, IRF3 and the STAT 17 
family; Active Motif, La Hulpe, Belgium) following the manufacturer’s recommendations. 18 
 19 
Statistical analyses 20 
Comparisons between conditions were performed by means of paired or unpaired non 21 
parametric tests (Wilcoxon test or Mann-Whitney test respectively). After the evaluation of the 22 
effects of rhinovirus infection (e.g. on interferon induction and/or transcription factors activation), 23 
in case of multiple tests, paired comparisons were performed using a Hierarchical method to control 24 
for multiplicity based on concentration, timing or modulatory intervention. A P-value of <0·05 was 25 
considered significant. All analyses were performed with GraphPad Prism 5.0 for Windows 26 
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 8 
(GraphPad Software, Inc., La Jolla, California). 1 
2 
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 9 
Results 1 
Effects of Th2 cytokines on rhinovirus-induced interferon production and rhinovirus 2 
replication 3 
To evaluate the effects of the Th2 status of the environment on rhinovirus-induced interferon 4 
(IFN) production, human bronchial epithelial cells (HBECs) and BEAS-2B cells were pre-treated 5 
with IL-4 and IL-13 prior to infection. Twenty-four-hour pre-treatment with IL-4 and IL-13 6 
produced significant dose-dependent inhibition of rhinovirus-induced IFN-β mRNA expression and 7 
IFN-β protein release at 8 hrs after infection in both the BEAS-2B cell line (Supplementary Figure 8 
1) and in HBECs (Figure 1A, 1C and 1E). Rhinovirus mediated induction of IFN-λ mRNA 9 
expression was also diminished 8 hrs after infection in both the BEAS-2B (Supplementary Figure 10 
1) and HBECs (Figure 1B and 1D). IFN-λ protein was undetectable in the cell culture supernatants 11 
of any of the experimental conditions assessed here. Neither IL-4 nor IL-13 had any modulatory 12 
effects on the rhinovirus-induced pro-inflammatory cytokine production, such as CXCL8 (Figure 13 
1F). IL-2 (used as control; Figure 1G and 1H) had no effect on rhinovirus-induced IFN induction. 14 
The inhibitory effect of Th2 cytokine pre-treatment on IFN production was observed at 8 but not 24 15 
hrs after the infection (Figure 2A-D). 16 
The impaired IFN expression following rhinovirus infection in the cell cultures that were 17 
pre-treated with Th2 cytokines was paralleled by increased rhinovirus replication in both the BEAS-18 
2B (data not shown) and HBECs (Figure 2E, 2F). Levels of IFN-β and IFN-λ mRNA and of 19 
rhinovirus vRNA were virtually undetectable (close to the lowest limit of detection) in uninfected 20 
cells and in cells stimulated only with Th2 cytokines (Figure 1 and 2).  21 
 22 
Effects of Th2 cytokines on rhinovirus-induced activation of transcription factors involved in 23 
interferon production and signalling. 24 
To investigate the mechanisms involved in the inhibitory effects of the Th2 cytokines on 25 
rhinovirus-induced IFN production, we evaluated the effects of IL-4 and IL-13 on rhinovirus-26 
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 10
induced activation of the transcription factors involved in interferon production, such as nuclear 1 
factor-kB (NF-kB) and IFN regulatory factor (IRF)-3 (24), and STAT1, which is a transcription 2 
factor that is activated by interferon-receptor engagement, and this activation leads to the 3 
transcription of IFN-stimulated genes (25). NF-kB, IRF-3 and STAT1 were activated 2 hrs after 4 
rhinovirus infection (Figure 3A-C). In the BEAS-2B epithelial cells, 12-hrs pre-treatment with IL-4 5 
(50 ng/ml) and IL-13 (25 ng/ml) significantly inhibited rhinovirus-induced IRF3 activation and 6 
subsequent STAT1 activation (Figure 3B and 3C) but also resulted in a slight increase of NF-kB 7 
activation that was not statistically significant (Figure 3A).  8 
 9 
Effects of antioxidants on Th2 cytokine-induced impairment of the innate immune response to 10 
rhinovirus. 11 
Pre-treatment with exogenous NAC (10 mM) 30 min before rhinovirus infection abolished 12 
the inhibitory effect of the 24-hr pre-treatment with Th2 cytokines on rhinovirus-induced IRF-3 13 
(Figure 4A) and STAT1 activations (Figure 4B) and restored the rhinovirus-induced expressions of 14 
IFN-λ (Figure 4C) and IFN-β mRNA (Figure 4D).  15 
 16 
Effects of Phosphoinositide 3-kinases (PI3K) on Th2 cytokine-induced impairment of the 17 
innate immune response to rhinovirus. 18 
 We found that pre-treatment with the phosphoinositide 3-kinases (PI3k) inhibitor LY294002 19 
(3.3 uM) before rhinovirus infection restored the inhibitory effect of Th-2 cytokines on rhinovirus 20 
induced IRF-3 activation, suggesting that the inhibition of phosphoinositide 3-kinases counteract 21 
the Th-2 induced impairment of the innate immune response to rhinovirus (Figure 4E). 22 
 23 
Effects of Th2 cytokines and oxidants on TLR3 expression.  24 
TLR-3 it is one of the key molecule activated by double stranded RNA produced during 25 
rhinovirus infection which in turn activates transcription factors such as nuclear factor (NF)-kB and 26 
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 11
IFN regulatory factor (IRF)-3/7 leading to the production of proinflammatory cytokines, 1 
chemokines and antiviral molecules including interferons (26-30). Twenty-four-hour IL-4 pre-2 
treatment significantly inhibited the baseline expression of TLR3 in the respiratory epithelial cells 3 
(Figure 5A). This inhibition was not affected by concomitant cell exposure to the antioxidant N-4 
acetyl cysteine (NAC, 10 mM; figure 5A).  5 
The expression of TLR3 mRNA was evaluated in the nasal epithelial cells from atopic 6 
rhinitis patients. Compared to the non-atopic healthy subjects, the expression of IL-4 mRNA was 7 
significantly higher in the primary nasal cells obtained from patients with atopic rhinitis, which 8 
confirms the Th2-related nature of the inflammatory process present in the upper airways of these 9 
subjects (Figure 5B). Conversely, TLR3 mRNA expression was significantly lower in the primary 10 
nasal cells obtained from patients with atopic rhinitis compared to those of healthy subjects (Figure 11 
5C).  Consistent with the latter finding, increased viral replication was observed in the primary 12 
cultures of the nasal epithelial cells from the atopic subjects compared to those of the controls 13 
(Figure 5D). 14 
 15 
16 
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Discussion 1 
Asthma is a chronic inflammatory disorder of the airways that is typically, although not 2 
always, characterized by enhanced Th2-type inflammation (31). In this study, we documented that 3 
Th2 cytokines (IL-4 and IL-13) impaired components of innate immunity, such as the production of 4 
types I (IFN- β) and III IFN (IFN- λ), in response to rhinovirus infection.  5 
The mechanisms by which a Th2 immunologic pattern inhibits virus-induced interferon 6 
production at the airway epithelial level, i.e. at the primary site of respiratory viral infections, 7 
remain largely unexplored. Here we evaluated the effects of Th2 cytokines over TLR-3 molecule 8 
and STAT1, IRF3 and NF-kB transcription factors, i.e. some of the key steps involved in rhinovirus 9 
induced interferon production (26-30). 10 
In line with previous observations (14), we found that Th2 cytokines inhibited rhinovirus-11 
induced IRF3 activation. We also found impaired activation of STAT1 following rhinovirus 12 
infection in the presence of Th2 cytokines. It has been previously reported that a) the exposure of 13 
epithelial cells to IL-4 and IL-13 cytokines leads to increased intracellular oxidative burst (32-34) 14 
and b) oxidative stress negatively interferes with intracellular interferon signalling, including IRF3 15 
activation (14,15) and interferon-induced JAK-STAT activation and signalling (15). Interestingly, 16 
here we show that the antioxidant NAC restores rhinovirus-mediated activation of IRF3 and STAT1 17 
and the downstream IFN-β and IFN-λ mRNA induction. These data suggest that the inhibition of 18 
oxidative stress represents a possible pharmacological approach to potentiate the innate immune 19 
responses to rhinovirus in a Th2 inflammatory milieu.  20 
Oxidative stress can also amplify the activation of the NF-kB transcription factors involved 21 
in virus-induced interferon production and/or inflammation (35). A recent study showed that 22 
rhinovirus-infected NF-kB p65-deficient mice exhibited reduced neutrophilic inflammation, while 23 
interferon induction, antiviral responses and viral loads were unaffected (29). In our study we found 24 
that IL-4 stimulation did not impair rhinovirus-induced NF-kB activation, while it affected 25 
rhinovirus induced interferon induction. Taken together, these experimental data confirm that NF-26 
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 13
kB is required for pro-inflammatory responses, but its role in interferon induction by rhinoviruses is 1 
not essential an may be redundant.  The fact that Th2 cytokines do not impair NF-kB activation is 2 
consistent with IL-4 and IL-13 having no effect on CXCL-8 induction in our model.  3 
The stimulation of the bronchial epithelial cell line BEAS-2B with Th2 inflammatory 4 
cytokines (IL-4 and IL-13) led to reduced baseline expression of TLR3 via a mechanism that was 5 
not mediated by oxidants. Similar results have previously been shown in human intestinal epithelial 6 
cells (36). Thus, the impaired IRF3 activation documented here might be the consequence of the 7 
Th2 mediated impairment of TLR3 expression (which leads to impaired IRF3 activation) and also 8 
the consequence of a direct Th2-induced oxidant-mediated effect. Interestingly, we showed for the 9 
first time in the present study reduced in vivo levels of TLR3 associated with enhanced Th2 10 
inflammation in the nasal epithelial cells of atopic rhinitis patients compared to normal controls. In 11 
line with these concepts, it has been recently shown that house dust mite (HDM)-sensitised mice 12 
have impaired rhinovirus-induced interferon production that is paralleled by a strong Th2-skewed 13 
inflammatory airway response (37). In addition, the pre-exposure of airway epithelial cells to HDM 14 
before rhinovirus infection deregulates TLR3-mediated production of cytokines and inflammatory 15 
mediators (38). Therefore HDM could suppress the IFN system either directly or via a Th-2 16 
mediated pathway, the latter requiring further investigation given that IL-4/IL-13 signalling is quite 17 
distinct from HDM signalling. Interestingly, recent in vivo observations suggest that the expression 18 
(39) and activity (40) of TLR3 are not impaired in the bronchial epithelial cells of mild asthmatic 19 
subjects compared to healthy subjects. These data might suggest that mechanisms other than those 20 
associated with the TLR pathways are involved in the impairment of interferon production in the 21 
bronchial epithelial cells of asthmatic subjects. It is possible that such impairments favour increased 22 
susceptibility to infections in specific subgroups of patients, e.g., those with more severe asthma 23 
and/or those patients with a predominant Th2 airway inflammation where such impairment is 24 
expected to be more pronounced-. It is also conceivable that impaired TLR3 expression in the upper 25 
respiratory tract i.e nasal mucosa could be a mechanism that is responsible for increased 26 
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susceptibility that is primarily compartmentalized to upper respiratory infections in Th2-oriented 1 
diseases such as atopic rhinitis.  2 
 Finally, we recently found that asthmatic children, irrespective of atopic status, and atopic 3 
children, irrespective of the presence of asthma, exhibit impaired immune responses at the bronchial 4 
epithelial level in terms of type I (IFN-β) and type III (IFN-λ) production after rhinovirus infection. 5 
Enhanced Th2-mediated airway inflammation is the common biological substrate between these 6 
children (7). In this study, we documented that the development of a Th2 environment negatively 7 
affects the molecular mechanisms that govern the innate immune responses to viral infections. 8 
Indeed, TLR3 expression was found to be impaired in the epithelial cells of the nasal mucosa of 9 
atopic patients. In accordance with this concept, we observed increased viral replication associated 10 
with increased IL-4 expression in the nasal mucosa of atopic rhinitis patients compared to normal 11 
subjects. These data support the concept that the Th2 inflammation can dampen the anti-viral 12 
response and make the Th2 environment even without asthma (e.g. allergic rhinitis) a more 13 
susceptible condition to viral infections. This concept is consistent with recent observations that 14 
subjects with atopic diseases (including asthma, rhinitis and dermatitis) experience more frequent 15 
upper and lower respiratory tract infections than do non-atopic controls (41). In this scenario any 16 
pharmacological approach able to down-regulate Th2 inflammation has the potential to recover a 17 
defective innate immune responses.  Previous studies showed that: a) IL-4 intracellular signalling 18 
leads to the activation of PI3k (20) and b) inhibition of PI3k resulted in attenuated Th2 19 
inflammatory response in a mouse model of allergic asthma (17) and enhanced TLR signalling 20 
(19,42). Interestingly, in our study we found that the inhibition of PI3k restored the inhibitory effect 21 
of 24 hr pre-treatment with Th-2 cytokines on rhinovirus induced IRF-3 activation, suggesting that 22 
the inhibition of phosphoinositide 3-kinases counteract the Th-2 induced impairment of the innate 23 
immune response to rhinovirus.  24 
In conclusion we showed that Th2 inflammation can dampen the anti-viral response and 25 
increase susceptibility viral infections of Th2 driven immunological conditions. In our experimental 26 
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 15
setting, pre-treatment with either antioxidants or inhibitors of PI3ks prevented the Th2-induced 1 
impairment of innate immune response to rhinovirus infection. Further studies are needed to 2 
elucidate more extensively at system biology level the complex interactions in the signalling 3 
pathways that links Th2 inflammation to impaired immune response to infections.  4 
5 
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Figure legends 1 
Figure 1. Dose-response effects of 24-hr pre-treatment with Th2 cytokines (IL-4: panel A and B – 2 
IL-13: panel C and D) on rhinovirus-induced interferon mRNA induction (IFN-β: panel A and C 3 
and IFN-λ: panel B and D) in human bronchial epithelial cells (HBEC) of non-atopic, non-4 
asthmatic subjects. Panel E: Effects of 24-hr pre-treatment with Th2 cytokines (IL-4 and IL-13) on 5 
rhinovirus (RV) 16-induced IFN-β production in HBECs (*p<0.01 vs. untreated and uninfected 6 
cells and IL-4- or IL-13-treated cells; ^p<0.05 vs. RV16 infected cells). Panel F: Effects of Th2 7 
cytokines (IL-4: 50 ng/ml and IL-13: 25 ng/ml) on rhinovirus-induced CXCL-8 production in 8 
HBECs (*p<0.01 vs. untreated and uninfected cells and IL-4- or IL-13-treated cells). Effects of IL-2 9 
on rhinovirus-induced IFN-β mRNA (Panel G) and IFN-λ mRNA (Panel H) in HBECs 10 
(***p<0.001; **p<0.01; *p<0.05; RV16: rhinovirus 16; f-RV16: cells inoculated with virus stock 11 
from which the virus had been removed by molecular weight filtration) (all panels n=6). 12 
 13 
Figure 2. Time course of the effects of 24-hr pre-treatment with Th2 cytokines (IL-4 and IL-13) on 14 
rhinovirus-induced IFN-β and IFN-λ mRNA induction and rhinovirus replication in human 15 
bronchial epithelial cells (HBECs). (**p<0.01; *p<0.05) (all panels n=6). 16 
 17 
Figure 3. Effects of 24-hr pre-treatment with Th2 cytokines (IL-4: 50 ng/ml and IL-13: 25 ng/ml) 18 
on rhinovirus-induced nuclear factor (NF)-kB (Panel A), interferon responsive factor 3 (IRF3; Panel 19 
B) and STAT1 (Panel C) activation in BEAS-2b cell (**p<0.01 and *p<0.05 vs. untreated and 20 
uninfected cells and IL-4- or IL-13-treated cells; ^p<0.05 vs. rhinovirus (RV) 16-infected cells) (all 21 
panels n=4). 22 
 23 
Figure 4. Effects of 24-hr pre-treatment with IL-4 (50 ng/ml) on rhinovirus (RV) 16-induced 24 
interferon responsive factor 3 (IRF3; Panel A) and STAT1 (Panel B) activation in the presence or 25 
absence of cell exposure to N-acetylcysteine (NAC, 10 mM) 30 minutes prior to infection 26 
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(**p<0.01; p<0.05). Effects of N-acetylcysteine (NAC, 10 mM) 30 minutes prior to infection on the 1 
inhibitory effects of 24-hr pre-treatment with IL-4 (50 ng/ml) on rhinovirus (RV) 16-induced IFN-λ 2 
mRNA in BEAS-2B cells (Panel C) and IFN-β mRNA (Panel D) (ns: not significant; *p<0.05). 3 
(Panel E) Effects of phosphoinositide 3-kinases (PI3k) inhibitor LY294002 (3.3 uM) before 4 
rhinovirus infection on the inhibitory effect of 24-hr pre-treatment with IL-4 (50 ng/ml) on 5 
rhinovirus (RV) 16-induced IRF-3 activation (*p<0.05 vs. untreated and uninfected cells; ^p<0.05 6 
vs. rhinovirus (RV) 16-infected cells and vs cells infected with RV16 and exposed to LY294002) 7 
(all panels n=5). 8 
 9 
Figure 5. Panel A) Effects of 24-hr pre-treatment with Th2 cytokines on TLR3 mRNA expression 10 
in BEAS-2B cells in the presence or absence of cell exposure to N-acetylcysteine (n=5). The 11 
expression of TLR3 was evaluated by real-time RT-PCR, the results were normalized to GAPDH, 12 
and the expression levels are represented as the fold-changes in expression vs. medium-treated cells 13 
(*p<0.05 vs. medium-treated cells). Panel B) Baseline IL-4 mRNA levels in the primary cell 14 
cultures of epithelial cells of the nasal mucosae of non-atopic (n=6) and atopic (n=5) subjects. Panel 15 
C) Baseline TLR3 mRNA levels in the primary cell cultures of epithelial cells of the nasal mucosae 16 
of non-atopic (n=6) and atopic subjects (n=5). D) Rhinovirus (RV) 16 vRNA levels 8 hr after the 17 
infection of primary nasal mucosa epithelial cells cultures of non-atopic (n=6) and atopic (n=5) 18 
subjects.   19 
 20 
 21 
22 
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